Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors
出版年份 2023 全文链接
标题
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors
作者
关键词
-
出版物
JOURNAL OF MEDICINAL CHEMISTRY
Volume -, Issue -, Pages -
出版商
American Chemical Society (ACS)
发表日期
2023-11-03
DOI
10.1021/acs.jmedchem.3c01724
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer
- (2023) Juanjuan Feng et al. ONCOGENE
- Drugging the Next Undruggable KRAS Allele-Gly12Asp
- (2022) Qinheng Zheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
- (2022) Marco H. Hofmann et al. Cancer Discovery
- A Structure Is Worth a Thousand Words: New Insights for RAS and RAF Regulation
- (2022) Dhirendra K. Simanshu et al. Cancer Discovery
- KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
- (2022) Zhongwei Mao et al. Cell Discovery
- Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening
- (2022) Ling Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- KRAS is vulnerable to reversible switch-II pocket engagement in cells
- (2022) James D. Vasta et al. Nature Chemical Biology
- Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention
- (2022) Christian Johnson et al. Cancer Discovery
- Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
- (2022) Jill Hallin et al. NATURE MEDICINE
- KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
- (2022) Sahar F. Bannoura et al. Frontiers in Oncology
- BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors
- (2021) Jiawei Guo et al. JOURNAL OF CLINICAL INVESTIGATION
- Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage
- (2021) Zilan Song et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
- (2021) Xiaolun Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
- (2020) Jay B. Fell et al. JOURNAL OF MEDICINAL CHEMISTRY
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
- (2020) Hao Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
- (2019) Brian A. Lanman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Therapeutic strategies to target RAS-mutant cancers
- (2018) Meagan B. Ryan et al. Nature Reviews Clinical Oncology
- Drugging RAS: Know the enemy
- (2017) Bjoern Papke et al. SCIENCE
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search